Prelude reports Q3 2026 results, advances KAT6A and JAK2V617F programs
Prelude says cash runway now extends into the second quarter of 2028 as its PRT13722 and PRT12396 trials continue enrolling.
SEC filing (2)
2 stories
Prelude says cash runway now extends into the second quarter of 2028 as its PRT13722 and PRT12396 trials continue enrolling.
SEC filing (2)
The company said it can now move PRT13722 into a Phase 1 trial in HR+/HER2- breast cancer, with enrollment targeted for the fourth quarter of 2026.
SEC filing